Pharming Group (LSE:0QCO) - Stock Price, News & Analysis

0QCO Stock Overview

Pharming Group N.V., empresa biofarmacéutica, desarrolla y comercializa terapias de sustitución de proteínas y medicamentos de precisión para el tratamiento de enfermedades raras en Estados Unidos, Europa y a escala internacional.

About the company

0QCO fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Cotiza un 52.9% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 74.6%

Trading a buen valor en comparación con empresas similares e industria

Los analistas coinciden en que el precio de las acciones subirá un 76.5%

Risk Analysis

Los accionistas se han diluido en el último año

Pharming Group N.V. Competitors

PureTech Health

LSE:PRTC

UK£589.1m

Genus

LSE:GNS

UK£1.1b

NIOX Group

AIM:NIOX

UK£272.2m

Bioventix

AIM:BVXP

UK£234.9m

Price History & Performance

Summary of all time highs, changes and price drops for Pharming Group
Historical stock prices
Current Share Price	€1.00
52 Week High	€1.31
52 Week Low	€0.94
Beta	0.73
1 Month Change	-5.10%
3 Month Change	-13.17%
1 Year Change	-8.99%
3 Year Change	-9.36%
5 Year Change	19.58%
Change since IPO	-89.99%

Recent updates

Shareholder Returns

	0QCO	GB Biotechs	GB Market
7D	-1.9%	-1.1%	-0.5%
1Y	-9.0%	-29.8%	0.4%

Rentabilidad frente al sector: 0QCO superó al sector UK Biotechs , que obtuvo un rendimiento del -27% el año pasado.

Rentabilidad vs. Mercado: 0QCO obtuvo unos resultados inferiores a los del mercado UK, que fue del 4.2% el año pasado.

Price Volatility

Is 0QCO's price volatile compared to industry and market?
0QCO volatility
0QCO Average Weekly Movement	5.1%
Biotechs Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0QCO no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0QCO (4%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
1988	382	Simon de Vries	https://www.pharming.com

Pharming Group N.V., empresa biofarmacéutica, desarrolla y comercializa terapias de sustitución proteica y medicamentos de precisión para el tratamiento de enfermedades raras en Estados Unidos, Europa y a escala internacional. La empresa ofrece RUCONEST, un inhibidor recombinante de la C1 esterasa para el tratamiento de ataques agudos en pacientes adultos y adolescentes con angioedema hereditario agudo (AEH); y Joenja (leniolisib), un inhibidor oral de PI3K? de molécula pequeña para el tratamiento del síndrome de fosfoinositido 3-cinasa delta activada.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
0QCO fundamental statistics
Market cap	€672.76m
Earnings (TTM)	-€9.73m
Revenue (TTM)	€226.38m

3.0x

P/S Ratio

-69.1x

P/E Ratio

Is 0QCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QCO income statement (TTM)
Revenue	US$245.32m
Cost of Revenue	US$25.21m
Gross Profit	US$220.10m
Other Expenses	US$230.65m
Earnings	-US$10.55m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 08, 2024

Earnings per share (EPS)	-0.016
Gross Margin	89.72%
Net Profit Margin	-4.30%
Debt/Equity Ratio	63.3%

How did 0QCO perform over the long term?

See historical performance and comparison

0QCO Stock Overview

Rewards

Risk Analysis

Pharming Group N.V. Competitors

LSE:PRTC

UK£589.1m

LSE:GNS

UK£1.1b

AIM:NIOX

UK£272.2m

AIM:BVXP

UK£234.9m

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Recent updates

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 26%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Now 20% undervalued

Now 22% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings released: EPS: US$0.014 (vs US$0 in 3Q 2021)

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

First quarter 2022 earnings released: EPS: US$0.005 (vs US$0.013 in 1Q 2021)

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe

Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST®

Second quarter 2021 earnings released: EPS €0.008 (vs €0.016 in 2Q 2020)

Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome

Independent Non-Executive Director has left the company

Independent Non-Executive Director has left the company

First quarter 2021 earnings released: EPS €0.011 (vs €0.013 in 1Q 2020)

Full year 2020 earnings released: EPS €0.052 (vs €0.058 in FY 2019)

Executive Director & CEO recently bought €489k worth of stock

Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021

Full year 2020 earnings released: EPS €0.051 (vs €0.058 in FY 2019)

Revenue beats expectations

Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €1.21

Pharming Group N.V. Announces Board Appointments

Revenue misses expectations

Third quarter 2020 earnings released: EPS €0.011